Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 1, 2010

FDA Requests $4.03 Billion for FY2011-a 23% Increase

The US Food and Drug Administration is requesting $4.03 billion to promote and protect public health as part of the President's fiscal year 2011 budget?a 23% increase over the agency?s current $3.28 billion budget.

The US Food and Drug Administration is requesting $4.03 billion to promote and protect public health as part of the President's fiscal year 2011 budget-a 23% increase over the agency's current $3.28 billion budget.

The FY 2011 request, which covers the period of Oct 1, 2010, through Sept 30, 2011, includes increases of $146 million in budget authority and $601 million in industry user fees. The budget for biologics has been increased by $23 million, to $329 million.

The budget request reflects the FDA's resolve to transform food safety practices, improve medical product safety, protect patients, and modernize FDA regulatory science to advance public health. The funding request also supports new regulatory authority to regulate cigarettes and other tobacco products received in June 2009.

The proposed budget includes support for the FDA's investment in addressing the challenges of the 21st century. The FDA envisions a transformed US food safety system that focuses on prevention, increased efforts to address medical product safety challenges, and a focus on modernizing regulatory science at the FDA.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.